Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00881452 · ClinicalTrials.gov registry record · Phase 3
A Trial of CM-AT in Children With Autism
A Phase 3 study of Autism, sponsored by Curemark.
- Completed
- Registry status
- Phase 3
- Development phase
- 182
- Enrollment target
- 19
- Study locations
NCT00881452: Completed Phase 3 study of Autism, sponsored by Curemark.
NCT00881452 is a Phase 3 study of Autism that has completed, run by Curemark. The registered enrollment target is 182 participants, roughly in line with the 182-participant average among 104 other Autism trials with a reported enrollment target. The trial reports 19 study locations across 15 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00881452, a Phase 3 study of Autism, has completed, sponsored by Curemark.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 182 participants
- Enrollment target
- 19
- Study locations
Study Summary
The purpose of this study is to determine whether CM-AT is safe and effective in treating the core symptoms of autism.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG CM-AT
Study Locations (19)
California
- University of California, Davis, M.I.N.D. Institute - Sacramento
- University of California, San Francisco - San Francisco
- Neuropsychiatric Research Center of Orange County - Santa Ana
Pennsylvania
- Hershey Medical Center - Hershey
- Drexel University - Philadelphia
- University of Pittsburgh - Pittsburgh
Arizona
- Southwest Autism Research and Resource Center - Phoenix
Florida
- Lake Mary Pediatrics - Orange City
Georgia
- Institute for Behavioral Medicine - Smyrna
Illinois
- Alexian Brothers Center for Psychiatric Research - Hoffman Estates
Louisiana
- Louisiana State University Health Science Center - Shreveport
New Jersey
- Saint Peters University Hospital - New Brunswick
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 182 participants |
| Start Date | 2009-05 |
| Est. Completion | 2011-09 |
| Phase | Phase 3 |
What the finished NCT00881452 record still lists
NCT00881452 is an interventional study that assigns participants to a tested intervention. The registered 182 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 182-participant average among 104 other Autism trials with a reported enrollment target.
The record links to 1 condition, with Autism appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00881452 lists 19 locations in 15 states (California, Pennsylvania, Arizona).
Frequently Asked Questions
What is clinical trial NCT00881452 about?
NCT00881452 is a clinical study titled "A Trial of CM-AT in Children With Autism". The purpose of this study is to determine whether CM-AT is safe and effective in treating the core symptoms of autism.
What is the current status of trial NCT00881452?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 182 participants. The study started on 2009-05. Estimated completion is 2011-09.
What conditions does trial NCT00881452 study?
This clinical trial studies the following conditions: Autism.
What interventions are being tested in trial NCT00881452?
The interventions under investigation include: Placebo (DRUG), CM-AT (DRUG).
Who is sponsoring clinical trial NCT00881452?
This trial is sponsored by Curemark, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00881452 being conducted?
This trial has 19 study locations across Arizona, California, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Autism
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00881452's enrollment target sits among peer trials
182 26th of 104 higher than 79 of 104 other Autism trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Autism trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
An Open Label Study of CM-AT for the Treatment of Children With Autism
ACTIVE NOT RECRUITING · Phase 3
-
Pediatric Open-Label Extension Study
COMPLETED · Phase 3
-
Study of Paliperidone ER in Adolescents and Young Adults With Autism
COMPLETED · Phase 3
-
A Pilot Study of Daytrana TM in Children With Autism Co-Morbid for Attention Deficit Hyperactivity Disorder (ADHD) Symptoms
COMPLETED · Phase 3
-
COMPASS Across Settings (CAST) for Improving Transition Outcomes for Students With ASD
RECRUITING · NA
-
Online Pivotal Response Treatment Training in Autism Spectrum Disorder
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03897998 · 182 participants · Phase 2
Neural Correlates of Hypoalgesia Driven by Observation
- NCT04300556 · 182 participants · Phase 1
A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
- NCT04323735 · 182 participants · Phase 2
Intravesical Lactobacillus for Urinary Symptoms Among People With NLUTD Who Use Indwelling Catheters
- NCT05606731 · 182 participants · NA
Family Intervention to Prevent Childhood Obesity
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia